Trial Outcomes & Findings for Blueberry Consumption and Type 2 Diabetes (NCT NCT02972996)

NCT ID: NCT02972996

Last Updated: 2022-04-19

Results Overview

Systolic blood pressure and diastolic blood pressure.

Recruitment status

COMPLETED

Study phase

Target enrollment

55 participants

Primary outcome timeframe

8 weeks

Results posted on

2022-04-19

Participant Flow

Participant milestones

Participant milestones
Measure	Blueberry Blueberry: 22 g freeze-dried whole blueberry powder	Placebo Placebo: 22 g placebo blueberry powder
Overall Study STARTED	27	28
Overall Study COMPLETED	26	26
Overall Study NOT COMPLETED	1	2

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Blueberry Consumption and Type 2 Diabetes

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Blueberry n=26 Participants Blueberry: 22 g freeze-dried whole blueberry powder	Placebo n=26 Participants Placebo: 22 g placebo blueberry powder	Total n=52 Participants Total of all reporting groups
Age, Continuous	67.1 years STANDARD_DEVIATION 1.1 • n=99 Participants	66.7 years STANDARD_DEVIATION 1.1 • n=107 Participants	67.0 years STANDARD_DEVIATION 1.1 • n=206 Participants
Sex: Female, Male Female	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants
Sex: Female, Male Male	26 Participants n=99 Participants	26 Participants n=107 Participants	52 Participants n=206 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants
Race (NIH/OMB) Asian	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants
Race (NIH/OMB) Black or African American	1 Participants n=99 Participants	2 Participants n=107 Participants	3 Participants n=206 Participants
Race (NIH/OMB) White	25 Participants n=99 Participants	24 Participants n=107 Participants	49 Participants n=206 Participants
Race (NIH/OMB) More than one race	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=99 Participants	0 Participants n=107 Participants	0 Participants n=206 Participants
Blood Pressure Systolic blood pressure	130.3 mm Hg STANDARD_DEVIATION 21.7 • n=99 Participants	126.2 mm Hg STANDARD_DEVIATION 13.3 • n=107 Participants	128.2 mm Hg STANDARD_DEVIATION 18.0 • n=206 Participants
Blood Pressure Diastolic blood pressure	73.4 mm Hg STANDARD_DEVIATION 5.4 • n=99 Participants	76.2 mm Hg STANDARD_DEVIATION 7.8 • n=107 Participants	74.8 mm Hg STANDARD_DEVIATION 6.8 • n=206 Participants

PRIMARY outcome

Timeframe: 8 weeks

Systolic blood pressure and diastolic blood pressure.

Outcome measures

Outcome measures
Measure	Blueberry n=26 Participants Blueberry: 22 g freeze-dried whole blueberry powder	Placebo n=26 Participants Placebo: 22 g placebo blueberry powder
Blood Pressure Systolic blood pressure	125.6 mm Hg Standard Error 2.5	126.0 mm Hg Standard Error 2.5
Blood Pressure Diastolic blood pressure	74.6 mm Hg Standard Error 1.0	75.1 mm Hg Standard Error 1.0

SECONDARY outcome

Timeframe: 8 weeks

Hemoglobin A1C is a surrogate marker of glycemic control over the preceding 2-3 months.

Outcome measures

Outcome measures
Measure	Blueberry n=26 Participants Blueberry: 22 g freeze-dried whole blueberry powder	Placebo n=26 Participants Placebo: 22 g placebo blueberry powder
Hemoglobin A1C	7.1 percent Standard Error 0.1	7.5 percent Standard Error 0.2

Adverse Events

Blueberry

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Placebo

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Margaret M. Wilson MS, RD, LD/N, CD/N, CNSC, CDE

Stratton V.A. Medical Center

Phone: 518 626-6889

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place